Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions

Respirology

Volumn 22, Issue 6, 2017, Pages 1171-1178

  Galli, Jonathan A ^a   Pandya, Aloknath ^a   Vega Olivo, Michelle ^a   Dass, Chandra ^a   Zhao, Huaqing ^a   Criner, Gerard J ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adverse event; drug tolerability; nintedanib; pirfenidone; pulmonary fibrosis

Indexed keywords

NINTEDANIB; PIRFENIDONE; ENZYME INHIBITOR; INDOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

AGED; ANOREXIA; ARTICLE; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; PHOTOSENSITIVITY; PRESCRIPTION; PRIORITY JOURNAL; RASH; SIDE EFFECT; TREATMENT OUTCOME; VOMITING; FIBROSING ALVEOLITIS; MIDDLE AGED; RETROSPECTIVE STUDY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ENZYME INHIBITORS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; MIDDLE AGED; PYRIDONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85017248204     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.13024     Document Type: Article

References (26)

1. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2002; 165: 277–304.
2. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 183: 431–40.
3. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788–824.
4. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur. Respir. Rev. 2011; 20: 85–97.
5. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008; 68: 4774–82.
6. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J. Pharmacol. Exp. Ther. 2014; 349: 209–20.
7. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2011; 365: 1079–87.
8. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083–92.
9. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071–82.
10. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760–9.
11. Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, Noble PW, Sahn SA, du Bois RM. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014; 19: 740–747.
12. Costabel U, Albera C, Cohen A, Bradford W, King T, Noble P, Sahn S, Valeyre D, du Bois RM. The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): interim data from the RECAP extension study [abstract]. Eur. Respir. J. 2011; 38(Suppl. 55): 174.
13. Crestani B, Ogura T, Pelling K, Quaresma M, Coeck C, Kaye M. Safety and tolerability of nintedanib in patients with IPF: interim analysis from an open-label extension of the INPULSIS® trials (INPULSIS®-ON) [abstract]. Am. J. Respir. Crit. Care Med. 2015; 191. [Abstract ID – 1020].
14. Ogura T, Azuma A, Inoue Y, Taniguchi H, Chida K, Bando M, Niimi Y, Kakutani S, Suga M, Sugiyama Y et al. All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respir. Investig. 2015; 53: 232–41.
15. Bando M, Yamauchi H, Ogura T, Taniguchi H, Watanabe K, Azuma A, Homma S, Sugiyama Y. Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis. Intern. Med. 2016; 55: 443–8.
16. Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. Rev. 2015; 24: 58–64.
17. Nieto Barbero MA, Valenzuela C, Rivera Ortega P. Pirfenidone in idiopathic pulmonary fibrosis (IPF): early Spanish experience with the European Named patient program (NPP) [abstract]. Eur. Respir. J. 2013; 42(Suppl. 57). [Abstract ID – 2361].
18. Okuda R, Hagiwara E, Baba T, Kitamura H, Kato T, Ogura T. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir. Med. 2013; 107: 1431–37.
19. Bonella F, Wessendorf TE, Costabel U. Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose [Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis]. Dtsch. Med. Wochenschr. 2013; 138: 518–23.
20. Chaudhuri N, Duck A, Frank R, Holme J, Leonard C. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir. Med. 2014; 108: 224–6.
21. Arai T, Inoue Y, Sasaki Y, Tachibana K, Nakao K, Sugimoto C, Okuma T, Akira M, Kitaichi M, Hayashi S. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir. Investig. 2014; 52: 136–43.
22. Oltmanns U, Kahn N, Palmowski K, Träger A, Wenz H, Heussel CP, Schnabel PA, Puderbach M, Wiebel M, Ehlers-Tenenbaum S et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration 2014; 88: 199–207.
23. Ravaglia C, Gurioli C, Romagnoli M. Pirfenidone treatment in idiopathic pulmonary fibrosis: an Italian case series [abstract]. Eur. Respir. J. 2013; 42(Suppl. 57): 3370. [Abstract ID – 3370].
24. Wijsenbeek MS, Grutters JC, Wuyts WA. Early experience of pirfenidone in daily clinical practice in Belgium and The Netherlands: a retrospective cohort analysis. Adv. Ther. 2015; 32: 691–704.
25. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur. Respir. J. 2011; 37: 356–63.
26. Kondoh Y, Taniguchi H, Katsuta T. Risk factors of acute exacerbation in idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2010; 27: 103–10.